0
0
Read Time:10 Second
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2025, titled “Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of beta-thalassemia”. |SUBJECT: Press Release
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
